$150–$400 per session at a clinic (no home devices appropriate for this therapy)

Evidence: Moderate — positive RCTs and observational studies in diabetic neuropathy, particularly for foot complications. Stronger evidence for wound healing applications. Less established for neuropathy pain relief specifically. FDA-cleared for diabetic foot wounds but not neuropathy as a standalone indication.

Hyperbaric oxygen therapy (HBOT) involves breathing 100 percent oxygen in a pressurized chamber that increases atmospheric pressure to 1.5 to 3 times normal. This significantly increases the amount of oxygen dissolved in blood plasma, delivering oxygen to tissues — including peripheral nerves — far beyond what is possible breathing normal air. For neuropathy, the rationale centers on the observation that peripheral nerve ischemia (inadequate oxygen delivery to nerve fibers) is a central mechanism of damage in diabetic and some other neuropathy types. By dramatically increasing tissue oxygenation, HBOT may protect surviving nerve fibers, reduce nerve ischemia-driven damage, and support healing of the small blood vessels that supply peripheral nerves. HBOT is a clinical treatment requiring specialized facility access — home versions of hyperbaric chambers exist but operate at insufficient pressures to replicate clinical outcomes. This is a treatment to discuss with your physician before pursuing.

How It Works

At normal atmospheric pressure, oxygen is carried in blood primarily bound to hemoglobin, with only a small fraction dissolved in plasma. Under hyperbaric conditions (2 to 3 atmospheres of pure oxygen), dissolved plasma oxygen increases by 10 to 15 times, allowing oxygen to diffuse deeply into tissues even when blood flow is impaired. For peripheral nerves with compromised microvascular supply — as in diabetic neuropathy — this increased dissolved oxygen can reach nerve fibers that are otherwise chronically hypoxic.

Beyond simple oxygenation, HBOT has been shown to trigger several beneficial downstream effects relevant to neuropathy: stimulation of angiogenesis (growth of new small blood vessels) in hypoxic tissues, enhanced white blood cell bactericidal activity (important for diabetic foot infections), reduction in tissue edema, and upregulation of growth factors including vascular endothelial growth factor (VEGF) and nerve growth factor. The combination of acute oxygen delivery and longer-term angiogenic and neurotrophic effects may explain why benefits in some studies persist beyond the treatment period.

Clinical Evidence

Several clinical studies have evaluated HBOT specifically for diabetic peripheral neuropathy. A 2018 RCT published in Undersea and Hyperbaric Medicine found that 30 HBOT sessions (2.4 atm, 90 minutes each, five days per week) significantly improved neuropathic symptom scores, vibration threshold, and nerve conduction velocity in diabetic neuropathy patients compared to controls. A 2021 study at a hyperbaric center in Israel found that HBOT improved both pain scores and intraepidermal nerve fiber density on skin biopsy — suggesting genuine nerve fiber regeneration in addition to symptom relief.

For diabetic foot ulcers — a serious complication directly linked to severe neuropathy — HBOT has FDA clearance and stronger evidence, with multiple trials showing improved wound healing rates and reduced amputation risk. The benefits seen in these wound healing trials likely reflect the same underlying mechanisms relevant to neuropathy: improved tissue oxygenation and angiogenesis. A Cochrane review of HBOT for chronic wounds found a significant benefit in wound healing compared to control.

The evidence in non-diabetic neuropathy types is more limited. Small studies in CIPN and idiopathic neuropathy are underway, but HBOT for neuropathy outside the diabetic context remains relatively understudied. The cost and access barriers make large-scale neuropathy trials challenging to conduct.

Home Use vs. Clinical Devices

Mild hyperbaric chambers (mHBOT) marketed for home use typically operate at 1.3 atmospheres and are used with atmospheric air rather than pure oxygen. These pressure levels are well below the 2.0 to 2.4 atmospheres used in evidence-based clinical trials, and the absence of 100 percent oxygen further reduces the oxygen delivery achievable. While mild hyperbaric chambers are generally safe and may provide some relaxation or mild oxygen benefit, they cannot replicate the clinical outcomes of medical-grade HBOT and should not be marketed or purchased as equivalent to clinic-based treatment.

For neuropathy, clinical HBOT at a licensed hyperbaric center using a hard-shelled chamber with 100 percent oxygen at 2.0 to 2.4 atmospheres is the appropriate standard. Soft-chamber mHBOT at home is a different and substantially less potent intervention. If you are considering home mHBOT for accessibility or cost reasons, discuss realistic expectations with your physician.

Finding a Hyperbaric Center and Managing Costs

Hyperbaric oxygen therapy is offered at hospital-based hyperbaric programs, freestanding wound care centers, and some private hyperbaric clinics. Hospital-based programs are most appropriate for medically complex patients, as they have immediate access to emergency medical support. For diabetic neuropathy patients with active foot wounds, physician referral to a wound care center using HBOT is straightforward and is often covered by Medicare and commercial insurance for this indication.

For neuropathy without active wounds, insurance coverage for HBOT is less certain. Medicare and most commercial plans cover HBOT for specific FDA-cleared indications (diabetic foot wounds, decompression sickness, radiation injury, etc.) but do not have a neuropathy-specific coverage policy. Out-of-pocket costs for a full 30-session course can range from $4,500 to $12,000 depending on location and facility. Some hyperbaric centers offer package pricing and financial counseling — contact the facility’s billing department before committing. Your physician’s documentation of medical necessity is critical for any insurance coverage discussion.

Pros

• Addresses the ischemic component of diabetic neuropathy through a fundamentally different mechanism than other therapies
• Growing evidence for nerve fiber regeneration — not just symptom management
• FDA-cleared for diabetic foot wounds — strong parallel evidence base in the same patient population
• Sessions are safe and well-tolerated for most patients in a clinical setting
• May provide a window of benefit that persists after the treatment course ends

Cons

• High cost per session and no insurance coverage for neuropathy as a standalone indication in most cases
• Requires access to a hyperbaric facility — not available in all areas
• 30-session standard protocol requires significant time commitment
• Contraindicated with certain lung conditions (emphysema with air trapping), recent ear surgery, and untreated pneumothorax

Frequently Asked Questions

Is hyperbaric oxygen therapy covered by Medicare for neuropathy?

Medicare covers HBOT for specific diagnoses including diabetic foot ulcers, but does not have a coverage policy for peripheral neuropathy as a standalone indication. Patients with diabetic neuropathy who also have active foot wounds may be able to access HBOT under the wound healing indication. For neuropathy without wounds, coverage requires a case-by-case prior authorization argument, and many claims are denied. Consult a hyperbaric center billing specialist for current coverage guidance.

What are the risks of hyperbaric oxygen therapy?

HBOT has a well-established safety profile when conducted in licensed clinical facilities. The most common side effect is middle ear barotrauma — ear pressure discomfort similar to flying — managed by learning equalization techniques. Oxygen toxicity seizures are rare at standard clinical pressures. Temporary near-vision changes (myopia) can occur with multi-week courses but typically reverse after treatment ends. Serious complications are uncommon and should be discussed with the hyperbaric medicine physician before starting treatment.

Can HBOT cure diabetic neuropathy?

No — HBOT is not a cure. The evidence supports meaningful improvement in neuropathic symptoms and nerve function measures in some patients, and there is preliminary evidence for nerve fiber regeneration. However, underlying diabetes must still be managed, and ongoing glycemic control is essential to prevent re-damage to nerves that have benefited from HBOT. HBOT is best thought of as a meaningful adjunctive treatment within a comprehensive neuropathy management plan.

How many HBOT sessions are needed for neuropathy?

Research protocols typically use 20 to 40 sessions, most commonly 30 sessions over 6 weeks (five days per week). Whether a shorter or longer course is appropriate for an individual patient depends on severity, response, and the judgment of the treating physician. Some hyperbaric centers offer re-evaluation at 10 to 15 sessions and adjust the plan based on early response.